CC-Cruiser
DeviceAn artificial intelligence to make comprehensive evaluation and treatment decision of congenital cataracts
NCT Number: NCT02748044
The prevention and treatment of diseases via artificial intelligence represents an ultimate goal in computational medicine. The artificial intelligence for systematic clinical application has not yet been successfully validated. Currently, the main prevention strategy for rare diseases is to build specialized care centers. However, these centers are scattered, and their coverage is insufficient, resulting in inadequate health care among a large proportion of rare disease patients. Here, the investigators use "deep learning" to create CC-Cruiser, an intelligence agent involving three functional networks: "pick-up networks" for diagnostics, "evaluation networks" for risk stratification and "strategist networks" to provide assisted treatment decisions. The investigator also establish a cloud intelligence platform for multi-hospital collaboration and conduct clinical trial and website-based study to validate its versatility.
Looking for future studies?
Notify MeUp to 80 year
All sexes
Interventional
Not applicable
Department of Ophthalmology, First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-
An artificial intelligence to make comprehensive evaluation and treatment decision of congenital cataracts
Time frame: Up to 4 years
Sun Yat-sen University
Other
Validation of the Utility of Rare Disease Intelligence Platform: A Multicenter Cluster Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03623971
Artificial Intelligence, Cataract
View Trial DetailsNCT07735000
Age Related Cataract, Cataract
Peshawar, KPK, Pakistan
View Trial DetailsNCT07605260
Cataract, Eye Diseases
Islamabad, Punjab Province, Pakistan
View Trial DetailsNCT06428955
Cataract, Eye Diseases
Indianapolis, Indiana, United States
View Trial Details